In this study, loganin treatment inhibited HFD- and OVX-induced weight gain and fat deposition reduced metabolic abnormalities, such as hepatic steatosis and adipocyte expansion, and increased the plasma levels of insulin and leptin. Here, INS is linked to fatty liver disease.